Pharmafile Logo
Pharmafocus logo
Advanced Search

paroxysmal nocturnal haemoglobinuria

Showing 2 posts of 2 posts found.

alexion_sign

European approval for Alexion’s Ultomiris in rare blood disease

July 4, 2019
Sales and Marketing Alexion, Europe, Ultomiris, paroxysmal nocturnal haemoglobinuria

Alexion has received marketing authorisation from the European Commission for its long-acting C5 complement inhibitor Ultomiris (ravulizumab) in the treatment …

News
alexion_sign

Investigational Alexion drug proves non-inferior to Soliris in rare blood disease

April 27, 2018
Medical Communications, Research and Development Alexion, paroxysmal nocturnal haemoglobinuria, pharma, soliris

Alexion has lifted the curtain on new data for its C5 complement inhibitor ALXN1210, demonstrating its non-inferiority to another of …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025